Decaris M, Rexhepaj M, Vowinckel J, Dupuis N, Wei Y, Hariri LP, Greenland JR, Chapman HA, Lee JS, Wolters PJ, Turner S. ATS Journals.
Urine represents an understudied source of biomarkers for interstitial lung disease. Noninvasive biomarkers that reliably predict disease progression and treatment response can benefit clinical trials. Here we applied global quantitative proteomics for biomarker discovery in urine samples from IPF patients and subsequently validated potential candidates using orthogonal ELISA assays.
Access our knowledge base with relevant resources and guiding information.